EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$95.97M
• Dividend Yield: 2.81%
• Average Volume (3M): 49.70K
• Price to Earnings (P/E): 14.0
• Beta (1Y): 0.16
• Revenue Growth: 0.65%
• EPS Growth: -9.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 47,043,200
• 10 Day Avg. Volume: 67,551
• 30 Day Avg. Volume: 49,696
• PEG Ratio: -2.57
• Price to Book (P/B): 3.85
• Price to Sales (P/S): 1.62
• P/FCF Ratio: 26.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: AU$2.50 ▲(72.41% Upside)

The score is driven primarily by strong profitability and a low-leverage balance sheet, partially offset by recent revenue and cash flow growth weakness. Technical indicators are mixed with signs of stretched momentum (negative MACD and elevated RSI/Stochastic), while valuation is supportive with a moderate P/E and modest dividend yield.

Positive Factors

High gross and net margins

Sustained gross margins above 70% with mid-single-digit net margins indicate durable pricing power and efficient product economics. This margin profile supports reinvestment in R&D, marketing, and distribution, allowing the business to sustain profitability through moderate demand swings.

Low leverage and strong capital structure

Very low debt levels and a solid equity ratio provide financial flexibility for strategic investments or downturns. Minimal leverage reduces refinancing and interest risk, enabling the firm to fund growth, absorb shocks, and maintain long-term R&D and product development without high fixed financing costs.

Multi-channel distribution and R&D emphasis

A multi-channel model (DTC e-commerce plus retail partnerships) diversified go-to-market risk and supports customer reach across channels. Combined with an R&D emphasis, this foundation promotes product innovation, repeatable sales, and structural ability to adapt offerings to changing consumer health trends over the medium term.

Negative Factors

Recent revenue decline

A material year-over-year revenue drop undermines top-line stability and constrains operating leverage. Persistent or recurrent declines reduce capacity to fund marketing and R&D internally, making long-term growth harder to achieve without either margin expansion or renewed revenue momentum.

Weak cash conversion and falling free cash flow growth

Subpar cash conversion and deteriorating free cash flow growth signal earnings may not translate reliably into discretionary cash. That limits internal funding for product development, inventory, and expansion, increasing reliance on external capital or cutting investments to preserve balance sheet health.

Volatile revenue and earnings growth

Volatile revenue and negative EPS growth reduce predictability for planning, impairing long-term contracts, supplier terms, and investor confidence. Persistent volatility makes scaling operations and forecasting cash needs harder, which can raise the cost of capital and hinder sustained strategic investments.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as grocery retailers. The company also designs, develops, produces, distributes, and sells consumer health products, including vitamins and dietary supplements, sports nutrition, weight management and wellbeing, herbal/traditional, and paediatric products under the EZZ brand through its e-commerce platforms and stores, such as Tmall Global. EZZ Life Science Holdings Limited was incorporated in 2015 and is based in Silverwater, Australia.

How the Company Makes Money

EZZ generates revenue through the sale of its dietary supplements and health products, which are marketed both online and through retail partnerships. The company employs a multi-channel distribution strategy, leveraging e-commerce platforms and traditional retail outlets to reach a broad audience. Key revenue streams include direct-to-consumer sales via their website and partnerships with health and wellness retailers. Additionally, EZZ may engage in strategic collaborations with other companies in the health sector to expand its product offerings and market reach, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. demonstrates strong profitability and a solid balance sheet with minimal leverage. However, recent declines in revenue and free cash flow growth highlight potential challenges in sustaining growth.

Income Statement

EZZ Life Science Holdings Ltd. shows strong profitability with a consistent gross profit margin above 70% and a net profit margin around 10%. However, the revenue growth rate has been volatile, with a significant decline of 10.88% in the latest year. Despite this, EBIT and EBITDA margins remain healthy, indicating efficient operations.

Balance Sheet

The company maintains a very low debt-to-equity ratio, indicating minimal leverage risk. Return on equity is robust, reflecting effective use of equity to generate profits. The equity ratio is solid, suggesting a strong capital structure with a high proportion of assets financed by equity.

Cash Flow

Cash flow metrics indicate some challenges, with a significant decline in free cash flow growth recently. The operating cash flow to net income ratio is below 1, suggesting potential issues in converting income into cash. However, the free cash flow to net income ratio is close to 1, showing that free cash flow generation is relatively aligned with net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.87M	66.87M	66.44M	37.14M	15.02M	22.29M
Gross Profit	49.72M	49.72M	50.95M	27.20M	7.51M	12.46M
EBITDA	10.08M	11.10M	10.38M	5.09M	1.90M	2.87M
Net Income	6.73M	6.73M	6.96M	3.63M	1.31M	2.03M
Balance Sheet
Total Assets	33.96M	33.96M	25.55M	17.64M	14.27M	12.04M
Cash, Cash Equivalents and Short-Term Investments	20.85M	20.85M	19.02M	13.83M	10.46M	8.85M
Total Debt	304.49K	304.49K	123.86K	478.59K	104.57K	79.01K
Total Liabilities	5.87M	5.87M	4.23M	3.06M	2.88M	1.93M
Stockholders Equity	28.09M	28.09M	21.32M	14.58M	11.39M	10.11M
Cash Flow
Free Cash Flow	4.13M	4.09M	5.73M	3.91M	1.89M	237.42K
Operating Cash Flow	4.37M	4.35M	6.14M	4.01M	1.90M	253.53K
Investing Cash Flow	-546.93K	-546.93K	-441.17K	-101.78K	-13.18K	-16.12K
Financing Cash Flow	-2.17M	-2.17M	-582.45K	-761.72K	-277.36K	5.44M

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.45
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Positive. The current price of 1.45 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.98, and below the 200-day MA of 2.02, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.82 is Neutral, neither overbought nor oversold. The STOCH value of 76.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	70 Outperform	AU$95.97M	13.99	27.24%	2.81%	0.65%	-9.90%
ATX	52 Neutral	AU$89.79M	-8.71	-27.39%	―	―	26.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMU	47 Neutral	AU$109.72M	-1.09	-83.09%	―	―	55.94%
RCE	44 Neutral	AU$189.42M	-7.27	―	―	―	0.66%
ALA	44 Neutral	AU$108.11M	-13.24	-47.98%	―	700.00%	26.88%
ATH	41 Neutral	AU$87.00M	-5.26	-42.68%	―	―	63.46%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Reports Lapse of Conditional Securities

EZZ Life Science Holdings has notified the market of the cessation of several classes of securities, with 10,000 performance rights and a total of 130,000 ordinary fully paid shares lapsing after the conditions attached to those securities were not met or became incapable of being satisfied between October 2025 and early January 2026. The lapses reduce potential future dilution from these conditional equity instruments and slightly adjust the company’s issued capital profile, but do not reflect any change in its core operations, instead signalling that certain performance or vesting hurdles tied to those securities were not achieved.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Director Increases Shareholding

EZZ Life Science Holdings Ltd. announced a change in the director’s interest, with Ivan Oshry increasing his direct shareholding by converting 5,000 performance rights into ordinary shares. This change reflects a strategic move in the company’s governance, potentially impacting shareholder confidence and market perception.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Announces Director Departure

EZZ Life Science Holdings Limited announced the cessation of Glenn Cross as a director effective 28 November 2025. This change in the board may influence the company’s strategic direction and could have implications for its stakeholders, as Cross held significant interests in the company, including 45,000 fully paid ordinary shares and 10,000 performance rights.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Appoints New Chief Strategy Officer to Drive Global Expansion

EZZ Life Science Holdings Limited has appointed Glenn Cross as Chief Strategy Officer after his tenure as Chair of the Board. With over 40 years of experience in the life-science sector, Cross will continue to contribute to EZZ’s strategic initiatives, including product development and international expansion, particularly in the United States. The company is also seeking a new Non-Executive Chair to support its evolving global footprint.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Announces AGM Results and Leadership Change

EZZ Life Science Holdings Limited announced the results of its Annual General Meeting, where the re-election of Mr. Glenn Cross as a director was withdrawn following his decision not to stand for re-election. The board expressed gratitude for his contributions, and CEO Mark Qin will serve as interim Chair. The announcement reflects ongoing leadership changes and strategic adjustments within the company, potentially impacting its governance and operational strategies.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Announces AGM Results and Leadership Changes

EZZ Life Science Holdings Limited announced the results of its Annual General Meeting, where the re-election of Mr. Glenn Cross as Director was withdrawn. Mr. Cross decided not to stand for re-election, and the company expressed gratitude for his contributions. CEO Mark Quinn will serve as interim Chair. The meeting also included the approval of a 7.1A mandate and the adoption of a remuneration report, reflecting ongoing governance and strategic adjustments within the company.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Reports Strong FY25 Performance and Strategic Expansion

EZZ Life Science Holdings Limited reported strong financial performance for FY25, with revenue reaching $66.9 million and a significant presence in Southeast Asia. The company achieved strategic milestones, including entering the U.S. market with FDA-registered products and expanding its Southeast Asian footprint through a distribution agreement. EZZ also launched 15 new products and enhanced its domestic retail presence. With a robust balance sheet and expanding international reach, EZZ is poised for sustained growth and enhanced shareholder value in FY26.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Declares Final Dividend for 2025

EZZ Life Science Holdings Limited has announced a fully franked final dividend of $0.020 per share for the fiscal year ending 30 June 2025. The dividend will be paid on 23 December 2025, with an ex-dividend date of 24 November 2025 and a record date of 25 November 2025. This announcement reflects the company’s commitment to rewarding shareholders and may enhance its attractiveness to investors.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Expands Market Reach and Product Line Amidst Financial Challenges

EZZ Life Science Holdings Limited reported its quarterly activities and financials for Q1 FY26, highlighting strategic progress in market expansion and product innovation. The company made significant strides in the US market by shifting its marketing strategy towards performance-driven campaigns and expanding its retail channels, including discussions to enter the Walmart Marketplace. Domestically, EZZ expanded its pharmacy network and launched a new Shopify store to boost its retail presence in Australia. Despite a 25.4% drop in customer receipts due to deferred payments and seasonal factors in China, EZZ maintained a strong cash position of $17.3 million and remains debt-free. The company launched three new health products, reinforcing its competitive edge and commitment to innovation. Looking forward, EZZ aims to scale its brand in the US, drive growth in Southeast Asia, and continue expanding its Australian retail channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces 2025 AGM with Digital Access

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting (AGM) scheduled for November 28, 2025. The company will provide meeting materials electronically, following recent legislative changes, to enhance accessibility and environmental sustainability. Shareholders are encouraged to participate and submit their votes in advance through various online and offline channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces Annual General Meeting Agenda

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting to be held on November 28, 2025. Key agenda items include the consideration of financial statements, the adoption of the remuneration report, the re-election of director Glenn Cross, and the approval of a mandate to issue equity securities. These resolutions are significant as they impact the company’s governance and capital structure, potentially influencing shareholder value and strategic direction.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.